Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 3/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935422 | 0.91 | THRA (0.43) | MEN1KMT2AMAPTL3MBTL1FABP4 | |
| SCHEMBL4933128 | 0.90 | TRPA1 (0.41) | MEN1KMT2AMAPTTSHRLMNA | |
| SCHEMBL4933325 | 0.90 | THRB (0.43) | MAPTL3MBTL1FABP4THRATHRB | |
| SCHEMBL4930968 | 0.90 | ALDH1A1 (0.42) | MEN1KMT2AMAPTL3MBTL1FABP4 | |
| SCHEMBL5105005 | 0.89 | TSHR (0.45) | MEN1KMT2AMAPTL3MBTL1FABP4 | |
| SCHEMBL5717833 | 0.87 | THRA (0.35) | MEN1KMT2ATHRATHRBMRGPRX4 | |
| SCHEMBL4931483 | 0.87 | TRPA1 (0.47) | MEN1KMT2AMAPTLMNAMRGPRX4 | |
| SCHEMBL5112689 | 0.86 | MEN1 (0.42) | MEN1KMT2AMAPTL3MBTL1FABP4 | |
| SCHEMBL4930955 | 0.86 | L3MBTL1 (0.40) | MEN1KMT2AMAPTL3MBTL1FABP4 | |
| SCHEMBL4925262 | 0.85 | THRB (0.42) | MEN1KMT2AMAPTLMNATHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | KARO BIO AB (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221210-A1 | Thyroid Receptor Agonists | TSHR, TRHR, THRA | MEN1 773/4885KMT2A 1742/4885MAPT 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.